Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA was delisted on the 25th of September, 2023.
146 hedge funds and large institutions have $841M invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2022 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 45 increasing their positions, 45 reducing their positions, and 15 closing their positions.
64% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $8.04M
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
0% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 45
5% less capital invested
Capital invested by funds: $884M → $841M (-$43M)
2% less funds holding
Funds holding: 149 → 146 (-3)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.6M |
| 2 |
D.E. Shaw & Co
New York
|
+$6.08M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$5.41M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.43M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$3.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.66M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$6.52M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.54M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$2.72M |
RETA Hedge Fund Activity: Q2 2022 in Review
146 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) for Q2 2022, worth a combined $841M — down 4.9% from $884M a quarter earlier.
Fund positioning in RETA was balanced in Q2 2022: 15 funds opened new positions, 15 closed out, 45 added to existing stakes and 45 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $30.6M. The largest seller was Wellington Management Group, cutting an estimated $11.5M.
- 146 institutional investors held Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) as of Q2 2022, down from 149 in Q1 2022.
- Funds reported $841M of Reata Pharmaceuticals, Inc. Class A Common Stock stock for Q2 2022, down 4.9% quarter-over-quarter.
- 15 funds opened new Reata Pharmaceuticals, Inc. Class A Common Stock positions in Q2 2022 and 15 closed out, a net change of 0 holders.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock buyer in Q2 2022 was Adage Capital Partners, an estimated $30.6M added.
- The largest Reata Pharmaceuticals, Inc. Class A Common Stock seller in Q2 2022 was Wellington Management Group, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2022.